Epigallocatechin-3-gallate enhances the therapeutic effects of Leptomycin B on human lung cancer A549 cells

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Cromie, Meghan M ^a   Gao, Weimin ^a  

^a TEXAS TECH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMINO ACIDS; BIOLOGICAL ORGANS; CELLS; DISEASES; DRUG PRODUCTS; RESPIRATORY SYSTEM;

ANTITUMOR PROPERTY; CLINICAL APPLICATION; COMBINATION TREATMENTS; EPIGALLOCATECHIN-3-GALLATE; MOLECULAR MECHANISM; MRNA EXPRESSION LEVEL; N-ACETYL-L-CYSTEINE; THERAPEUTIC EFFECTS;

CYTOLOGY;

ACETYLCYSTEINE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 3A4; EPIGALLOCATECHIN GALLATE; GLUTATHIONE PEROXIDASE 1; LEPTOMYCIN B; MESSENGER RNA; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; CATECHIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTOCHROME P450 3A; GLUTATHIONE PEROXIDASE; INHIBITOR OF APOPTOSIS PROTEIN; UNSATURATED FATTY ACID;

A549 CELL LINE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG METABOLISM; ENZYME INACTIVATION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; APOPTOSIS; DRUG EFFECTS; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CATECHIN; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOCHROME P-450 CYP3A; DOWN-REGULATION; FATTY ACIDS, UNSATURATED; GLUTATHIONE PEROXIDASE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; UP-REGULATION;

EID: 84928380166     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/217304     Document Type: Article

References (66)

1. Cancer Facts and Figures, American Cancer Society, 2014.
2. S. K. Pal, R. A. Figlin, and K. Reckamp, "Targeted therapies for non-small cell lung cancer: an evolving landscape," Molecular CancerTherapeutics, vol. 9, no. 7, pp. 1931-1944, 2010.
3. W. C. M. Dempke, T. Suto, and M. Reck, "Targeted therapies for non-small cell lung cancer," Lung Cancer, vol. 67, no. 3, pp. 257-274, 2010.
4. M. Yoshida, M. Nishikawa, K. Nishi, K. Abe, S. Horinouchi, and T. Beppu, "Effects of leptomycin B on the cell cycle of fibroblasts and fission yeast cells," Experimental Cell Research, vol. 187, no. 1, pp. 150-156, 1990.
5. K. T. Nguyen, M. P. Holloway, and R. A. Altura, "The CRM1 nuclear export protein in normal development and disease," International Journal of Biochemistry andMolecular Biology, vol. 3, no. 2, pp. 137-151, 2012.
6. N. Kudo, N. Matsumori, H. Taoka et al. , "Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 16, pp. 9112-9117, 1999.
7. K. Komiyama, K. Okada, S. Tomisaka, I. Umezawa, T. Hamamoto, and T. Beppu, "Antitumor activity of leptomycin B," Journal of Antibiotics, vol. 38, no. 3, pp. 427-429, 1985.
8. W. R. Leopold, J. L. Shillis, A. E. Mertus, J. M. Nelson, B. J. Roberts, and R. C. Jackson, "Anticancer activity of the structurally novel antibiotic CI-920 and its analogues," Cancer Research, vol. 44, no. 5, pp. 1928-1932, 1984.
9. B. J. Roberts, K. L. Hamelehle, J. S. Sebolt, and W. R. Leopold, "In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721)," Cancer Chemotherapy And Pharmacology, vol. 16, no. 2, pp. 95-101, 1986.
10. J. B. Tunac, B. D. Graham, W. E. Dobson, and M. D. Lenzini, "Novel antitumor antibiotics, CI-940 (PD 114,720) and PD 114,721. Taxonomy, fermentation and biological activity," Journal of Antibiotics, vol. 38, no. 4, pp. 460-465, 1985.
11. C. Lu, C. Shao, E. Cobos, K. P. Singh, and W. Gao, "Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin," PLoS ONE, vol. 7, no. 3, Article ID e32895, 2012.
12. C. Shao, C. Lu, L. Chen, P. P. Koty, E. Cobos, and W. Gao, "p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma," Cancer Chemotherapy and Pharmacology, vol. 67, no. 6, pp. 1369-1380, 2011.
13. E. S. Newlands, G. J. S. Rustin, and M. H. Brampton, "Phase I trial of elactocin," British Journal of Cancer, vol. 74, no. 4, pp. 648-649, 1996.
14. W. Y. Feng, "Metabolism of green tea catechins: an overview," Current Drug Metabolism, vol. 7, no. 7, pp. 755-809, 2006.
15. M. D. Brown, "Green tea (Camellia sinensis) extract and its possible role in the prevention of cancer," Alternative Medicine Review, vol. 4, no. 5, pp. 360-370, 1999.
16. C.-H. Kim and S.-K. Moon, "Epigallocatechin-3-gallate causes the p21/WAF1-mediated G1-phase arrest of cell cycle and inhibits matrix metalloproteinase-9 expression in TNF-α-induced vascular smoothmuscle cells," Archives of Biochemistry and Biophysics, vol. 435, no. 2, pp. 264-272, 2005.
17. R. L. Thangapazham, A. K. Singh, A. Sharma, J. Warren, J. P. Gaddipati, and R. K. Maheshwari, "Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo," Cancer Letters, vol. 245, no. 1-2, pp. 232-241, 2007.
18. W. S. Ahn, S. W. Huh, S.-M. Bae et al. , "A major constituent of green tea, EGCG, inhibits the growth of a human cervical cancer cell line, CaSki cells, through apoptosis, G1 arrest, and regulation of gene expression," DNA and Cell Biology, vol. 22, no. 3, pp. 217-224, 2003.
19. S. Shankar, S. Ganapathy, S. R. Hingorani, and R. K. Srivastava, "EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer," Frontiers in Bioscience, vol. 13, no. 2, pp. 440-452, 2008.
20. X.-W. Yang, X.-L. Wang, L.-Q. Cao et al. , "Green tea polyphenol epigallocatechin-3-gallate enhances 5-fluorouracil-induced cell growth inhibition of hepatocellular carcinoma cells," Hepatology Research, vol. 42, no. 5, pp. 494-501, 2012.
21. W. Zhu, M. M. Cromie, Q. Cai, T. Lv, K. Singh, and W. Gao, "Curcumin and vitamin E protect against adverse effects of benzo[a]pyrene in lung epithelial cells," PLoS ONE, vol. 9, no. 3, Article ID e92992, 2014.
22. K. M. Yang, B. M. Kim, and J.-B. Park, "ω-Hydroxyundec-9-enoic acid induces apoptosis through ROS-mediated endoplasmic reticulum stress in non-small cell lung cancer cells," Biochemical and Biophysical Research Communications, vol. 448, no. 3, pp. 267-273, 2014.
23. B. R. You and W. H. Park, "Zebularine inhibits the growth of A549 lung cancer cells via cell cycle arrest and apoptosis," Molecular Carcinogenesis, vol. 53, pp. 847-857, 2014.
24. A. Ganguli, D. Choudhury, S. Datta, S. Bhattacharya, and G. Chakrabarti, "Inhibition of autophagy by chloroquine potentiates synergistically anti-cancer property of artemisinin by promoting ROS dependent apoptosis," Biochimie, vol. 107, part B, pp. 338-349, 2014.
25. J. Guo,G. Wu, J. Bao,W. Hao, J. Lu, and X. Chen, "Cucurbitacin B induced ATM-mediated DNA damage causes G2/M cell cycle arrest in a ROS-dependent manner," PLoS ONE, vol. 9, no. 2, Article ID e88140, 2014.
26. L. Li, P. Qiu, B. Chen et al. , "Reactive oxygen species contribute to arsenic-induced EZH2 phosphorylation in human bronchial epithelial cells and lung cancer cells," Toxicology and Applied Pharmacology, vol. 276, no. 3, pp. 165-170, 2014.
27. G.-X. Li, Y.-K. Chen, Z. Hou et al. , "Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro," Carcinogenesis, vol. 31, no. 5, pp. 902-910, 2010.
28. H. D. Hoon, J. H. Jeong, and H. J. Kim, "Anti-proliferative and apoptosis induction activity of green tea polyphenols on human promyelocytic leukemia HL-60 cells," Anticancer Research, vol. 29, no. 4, pp. 1417-1422, 2009.
29. H. Inoue, M. Maeda-Yamamoto, A. Nesumi, and A. Murakami, "Delphinidin-3-O-galactoside protects mouse hepatocytes from (-)-epigallocatechin-3-gallate-induced cytotoxicity via up-regulation of heme oxygenase-1 and heat shock protein 70," Nutrition Research, vol. 32, no. 5, pp. 357-364, 2012.
30. F. Farabegoli, C. Barbi, E. Lambertini, and R. Piva, "(-)-Epigallocatechin-3-gallate downregulates estrogen receptor alpha function inMCF-7 breast carcinoma cells," Cancer Detection and Prevention, vol. 31, no. 6, pp. 499-504, 2007.
31. J. I. Sonoda, R. Ikeda, Y. Baba et al. , "Green tea catechin, epigallocatechin-3-gallate, attenuates the cell viability of human non-small-cell lung cancer A549 cells via reducing Bcl-xL expression," Experimental andTherapeutic Medicine, vol. 8, no. 1, pp. 59-63, 2014.
32. Y. Sakamoto, N. Terashita, T. Muraguchi, T. Fukusato, and S. Kubota, "Effects of epigallocatechin-3-gallate (EGCG) on a549 lung cancer tumor growth and angiogenesis," Bioscience, Biotechnology and Biochemistry, vol. 77, no. 9, pp. 1799-1803, 2013.
33. M. Masuda, M. Suzui, J. T. E. Lim, and I. B. Weinstein, "Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells," Clinical Cancer Research, vol. 9, no. 9, pp. 3486-3491, 2003.
34. G. Liang, A. Tang,X. Lin et al. , "Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mousemodel for chemoresistant liver cancer," International Journal of Oncology, vol. 37, no. 1, pp. 111-123, 2010.
35. C.-M. Chang, P.-Y. Chang, M.-G. Tu et al. , "Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2," Oncology Reports, vol. 28,no. 5, pp. 1799-1807, 2012.
36. Y. Liang, S. Lin-shiau, C. Chen, and J. Lin, "Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells," Journal of Cellular Biochemistry, vol. 67, no. 1, pp. 55-65, 1997.
37. M. Suganuma, A. Saha, and H. Fujiki, "New cancer treatment strategy using combination of green tea catechins and anticancer drugs," Cancer Science, vol. 102, no. 2, pp. 317-323, 2011.
38. K.-C. Kim and C. Lee, "Reversal of cisplatin resistance by epigallocatechin gallate is mediated by downregulation of Axl and Tyro 3 expression in human lung cancer cells," The Korean Journal of Physiology and Pharmacology, vol. 18, no. 1, pp. 61-66, 2014.
39. W. Gao, C. Lu, L. Chen, and P. Keohavong, "Overexpression of CRM1: a characteristic feature in a transformed phenotype of lung carcinogenesis and a molecular target for lung cancer adjuvant therapy," Journal ofThoracic Oncology, 2015.
40. M. Niu, S. Wu, L. Mao, and Y. Yang, "CRM1 is a cellular target of curcumin: new insights for themyriad of biological effects of an ancient spice," Traffic, vol. 14, no. 10, pp. 1042-1052, 2013.
41. K. Sakakibara, N. Saito, T. Sato et al. , "CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity," Blood, vol. 118, no. 14, pp. 3922-3931, 2011.
42. S. C. Mutka, W. Q. Yang, S. D. Dong et al. , "Identification of nuclear export inhibitors with potent anticancer activity in vivo," Cancer Research, vol. 69, no. 2, pp. 510-517, 2009.
43. S. Wang, X. Han, J. Wang, J. Yao, and Y. Shi, "Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and inmouse tumor xenografts," PLoS ONE, vol. 9, no. 3,Article ID e89848, 2014.
44. S. C. Forester and J. D. Lambert, "The role of antioxidant versus pro-oxidant effects of green tea polyphenols in cancer prevention,"Molecular Nutrition and Food Research, vol. 55, no. 6, pp. 844-854, 2011.
45. I. F. F. Benzie and Y. T. Szeto, "Total antioxidant capacity of teas by the ferric reducing/antioxidant power assay," Journal of Agricultural and Food Chemistry, vol. 47, no. 2, pp. 633-636, 1999.
46. C. H. Coyle, B. J. Philips, S. N. Morrisroe, M. B. Chancellor, and N. Yoshimura, "Antioxidant effects of green tea and its polyphenols on bladder cells," Life Sciences, vol. 83, no. 1-2, pp. 12-18, 2008.
47. T. Nakazato, K. Ito, Y. Miyakawa et al. , "Catechin, a green tea component, rapidly induces apoptosis ofmyeloid leukemic cells via modulation of reactive oxygen species production in vitro and inhibits tumor growth in vivo," Haematologica, vol. 90, no. 3, pp. 317-325, 2005.
48. Y. Li, S. Zhao, W. Zhang et al. , "Epigallocatechin-3-O-gallate (EGCG) attenuates FFAs-induced peripheral insulin resistance through AMPK pathway and insulin signaling pathway in vivo," Diabetes Research and Clinical Practice, vol. 93, no. 2, pp. 205-214, 2011.
49. B.-C. Jang, U. Munoz-Najar, J.-H. Paik, K. Claffey, M. Yoshida, and T. Hla, "Leptomycin B, an inhibitor of the nuclear export receptor CRM1, inhibits COX-2 expression," Journal of Biological Chemistry, vol. 278, no. 5, pp. 2773-2776, 2003.
50. N. J. Plant and G. G. Gibson, "Evaluation of the toxicological relevance of CYP3A4 induction," Current Opinion in Drug Discovery and Development, vol. 6, no. 1, pp. 50-56, 2003.
51. D. Tian and Z. Hu, "CYP3A4-mediated pharmacokinetic interactions in cancer therapy," Current DrugMetabolism, vol. 15, no. 8, pp. 808-817, 2014.
52. T. Nakamura, E. Asada, Y. Nagata, and H. Kanazawa, "Effect of metabolic inhibition against CYP3A4 by catechins in bottled green tea drinks," Bunseki Kagaku, vol. 52, no. 9, pp. 769-773, 2003.
53. A. E. Yuzhalin and A. G. Kutikhin, "Inherited variations in the SOD and GPX gene families and cancer risk," Free Radical Research, vol. 46, no. 5, pp. 581-599, 2012.
54. S. Song, Y. W. Huang, Y. Tian, X. J. Wang, and J. Sheng, "Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent activation of extracellular signalregulated kinase 1/2 in Jurkat cells," Chinese Journal of Natural Medicines, vol. 12, no. 9, pp. 654-662, 2014.
55. H. H. Tang,M. Zhou, and G. Liang, "Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU," Ai Zheng, vol. 27, no. 10, pp. 1056-1064, 2008.
56. S. G. Khan, S. K. Katiyar, R. Agarwal, and H. Mukhtar, "Enhancement of antioxidant and phase II enzymes by oral feeding of green tea polyphenols in drinking water to SKH-1 hairless mice: possible role in cancer chemoprevention," Cancer Research, vol. 52, no. 14, pp. 4050-4052, 1992.
57. D. Liu, X. Zhang, L. Jiang, Y. Guo, and C. Zheng, "Epigallocatechin-3-gallate (EGCG) attenuates concanavalin A-induced hepatic injury in mice," Acta Histochemica, vol. 116, no. 4, pp. 654-662, 2014.
58. H. Fujiki, M. Suganuma, M. Kurusu et al. , "New TNF-α releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with EGCG and sulindac or tamoxifen," Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 523-524, pp. 119-125, 2003.
59. Y. Xiong,G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach, "p21 is a universal inhibitor of cyclin kinases," Nature, vol. 366, no. 6456, pp. 701-704, 1993.
60. A. Marchetti, C. Doglioni, M. Barbareschi et al. , "P21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation," Oncogene, vol. 12, no. 6, pp. 1319-1324, 1996.
61. T. Shoji, F. Tanaka, T. Takata et al. , "Clinical significance of p21 expression in non-small-cell lung cancer," Journal of Clinical Oncology, vol. 20, no. 18, pp. 3865-3871, 2002.
62. T. Sasaki, M. B. S. Lopes, G. R. Hankins, and G. A. Helm, "Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system," Acta Neuropathologica, vol. 104, no. 1, pp. 105-109, 2002.
63. K. S. Chan, C. H. Wong, Y. F. Huang, and H. Y. Li, "Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis," Cell Death and Disease, vol. 1, article e57, 2010.
64. C. Onoda, K. Kuribayashi, S. Nirasawa et al. , "(-)-Epigallocatechin-3-gallate induces apoptosis in gastric cancer cell lines by down-regulating survivin expression," International Journal of Oncology, vol. 38, no. 5, pp. 1403-1408, 2011.
65. Y. Tang, D. Y. Zhao, S. Elliott et al. , "Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression," International Journal of Oncology, vol. 31, no. 4, pp. 705-711, 2007.
66. M. M. Hossain,N. L. Banik, and S. K. Ray, "Survivin knockdown increased anti-cancer effects of (-)-epigallocatechin-3-gallate in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells," Experimental Cell Research, vol. 318, no. 13, pp. 1597-1610, 2012.